Tanja Kuehbacher
- Genetics top 5%
- Inflammatory Bowel Disease 29
- Chronic Lymphocytic Leukemia Research 7
- Hematology top 10%
- Chronic Myeloid Leukemia Treatments 4
-
- Immunodeficiency and Autoimmune Disorders 4
- Gastroenterology top 10%
- Epidemiology top 10%
- Microscopic Colitis 13
-
- Eosinophilic Esophagitis 3
- Helicobacter pylori-related gastroenterology studies 3
-
- Liver Diseases and Immunity 3
- Co-authors
- Stefan SchreiberAnnegret Van der AaMaria KłopockaSéverine VermeireRóbert SikeRobert PetrykaAdrian GoldișPille Harrison
- Cited by
- GeneticsHematologyImmunology
In The Last Decade
Tanja Kuehbacher
33 papers receiving 726 citations
Hit Papers
Peers
Comparison fields: 5 of 82
- Genetics 422
- Hematology 97
- Immunology 172
- Gastroenterology 43
- Epidemiology 261
Countries citing papers authored by Tanja Kuehbacher
This map shows the geographic impact of Tanja Kuehbacher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tanja Kuehbacher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tanja Kuehbacher more than expected).
Fields of papers citing papers by Tanja Kuehbacher
This network shows the impact of papers produced by Tanja Kuehbacher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tanja Kuehbacher. The network helps show where Tanja Kuehbacher may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Tanja Kuehbacher, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 0 | |
| 3 | 2023 | 2 | |
| 4 | 2022 | 1 | |
| 5 | 2022 | 20 | |
| 6 | 2021 | 18 | |
| 7 | 2017 | 1 | |
| 8 | 2017 | 1 | |
| 9 | 2017 | 4 | |
| 10 | Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trialbreakdown → | 2016 | 344 |
| 11 | Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn's disease: interim analysis from the Phase 2 FITZROY study | 2016 | 5 |
| 12 | 2014 | 59 | |
| 13 | 2012 | 22 | |
| 14 | 2011 | 3 | |
| 15 | 2011 | 2 | |
| 16 | 2011 | 4 | |
| 17 | 2011 | 2 | |
| 18 | 2008 | 21 | |
| 19 | 2003 | 2 | |
| 20 | 2001 | 10 |
About Tanja Kuehbacher
Tanja Kuehbacher is a scholar working on Genetics, Genetics, Hematology, Epidemiology and Hepatology, having authored 34 papers that have together received 733 indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (29 papers), Microscopic Colitis (13 papers), Chronic Lymphocytic Leukemia Research (7 papers), Immunodeficiency and Autoimmune Disorders (4 papers), Chronic Myeloid Leukemia Treatments (4 papers), Eosinophilic Esophagitis (3 papers), Helicobacter pylori-related gastroenterology studies (3 papers) and Liver Diseases and Immunity (3 papers). The work is most often cited by research in Genetics (422 citations), Hematology (97 citations), Immunology (172 citations), Gastroenterology (43 citations) and Epidemiology (261 citations). Tanja Kuehbacher has collaborated with scholars based in Germany, Russia and Belgium. Frequent co-authors include Stefan Schreiber, Annegret Van der Aa, Maria Kłopocka, Séverine Vermeire, Róbert Sike, Robert Petryka, Adrian Goldiș, Pille Harrison, Chantal Tasset and Xavier Roblin. Their work appears in journals such as Gastroenterology, Journal of Crohn s and Colitis, Expert Opinion on Drug Safety, Alimentary Pharmacology & Therapeutics and Gastrointestinal Endoscopy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.